Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Current Deferred Revenue (2024 - 2025)

Lipocine's Current Deferred Revenue history spans 2 years, with the latest figure at $320000.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue changed N/A year-over-year to $320000.0; the TTM value through Sep 2025 reached $320000.0, changed N/A, while the annual FY2024 figure was $320000.0, N/A changed from the prior year.
  • Current Deferred Revenue reached $320000.0 in Q3 2025 per LPCN's latest filing, roughly flat from $320000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $320000.0 in Q4 2024 to a low of $320000.0 in Q4 2024.